Dr. Wyatt receives a CIHR Early Career Investigator Award

Date Posted: 
2017-12-07

Dr. Alex Wyatt has been awarded a CIHR Early Career Investigator Award for $345,000 over 3 years.  His project aims to develop a procedure that will enable the identification of metastatic bladder cancer patients most likely to respond to specific therapies.

Chemotherapy has historically been the most effective treatment for metastatic disease, but long-term survival has been a rarity. Recently, new drugs including immunotherapies are showing significant promise, but only a small proportion of patients respond to these treatments and there currently is no reliable way of predicting who the responders will be.

Dr. Wyatt established the groundwork for this project during the first three years of his faculty appointment, during which time he worked closely with clinical collaborators to develop a blood test that can identify tumor DNA present in a small blood sample. Preliminary work with this circulating tumor DNA (ctDNA) suggests that mutations detected in ctDNA accurately reflect cancer itself, meaning that a patient’s metastatic bladder cancer can be profiled without the need for a tissue biopsy (see Vandekerkhove et. al., Clin Cancer Res. 2017 Nov 1;23(21):6487-6497 PMID: 28760909).

His awarded project,"Circulating tumour DNA as a precision oncology tool for metastatic bladder cancer," will identify mutations in the ctDNA of hundreds of Canadians with metastatic bladder cancer that are being treated with chemotherapy or immunotherapy. His research team will determine which mutations can predict a patient’s subsequent response to treatment using our rare combination of cancer bioinformatics and clinical oncology. Success with this project will help explain why some metastatic bladder cancers are intrinsically responsive or resistant to the most commonly used therapies. Furthermore, Dr. Wyatt and his team will have developed a clinically-practical framework (requiring only a blood sample) that may ultimately help align patients with therapies which would provide the best chance of success.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Robbie Burns celebration

Robbie Burns Gala at the Pan Pacific Vancouver: January 25

The Pan Pacific Vancouver is hosting a celebration of Scotland's most famous poet, Robbie Burns, on January 25.  The event will include fundraising for Prostate Cancer Canada's Plaid for Dad campaign. There will be a traditional itinerary, starting with the official piping in of the guests, with exclusive malt tastings, authentic Scottish cuisine celebrating the haggis and ending the evening with a chorus of Auld Lang Syne. Click here for more information and tickets.

It's a Snow Day poster

It's A Snow Day at Mt. Seymour: March 9

Mt. Seymour is hosting It's A Snow Day, a fundraiser for Prostate Cancer Foundation BC, on Friday March 9. The event will include slope time, a reception, and a silent auction. Click here for more details including how to register, donate and/or sponsor.

 

 

Employment

Work at the Vancouver Prostate Centre

Monday, January 30, 2017

Dr. Amina Zoubeidi leads identification of gene linked to growth of aggressive neuroendocrine prostate cancer (NEPC)

DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.